tabirafusp alfa (KSI-101) / Kodiak Sciences - LARVOL DELTA

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Kodiak Sciences Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Inflammation • Macular Edema • Ophthalmology

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Kodiak Sciences Inc | Not yet recruiting ➔ Recruiting | Trial primary completion date: Dec 2026 ➔ Feb 2026

Enrollment open • Trial primary completion date • Inflammation • Macular Edema • Ophthalmology

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE (clinicaltrials.gov) - P3 | N=150 | Not yet recruiting | Sponsor: Kodiak Sciences Inc

New P3 trial • Inflammation • Macular Edema • Ophthalmology

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK (clinicaltrials.gov) - P3 | N=150 | Not yet recruiting | Sponsor: Kodiak Sciences Inc

New P3 trial • Inflammation • Macular Edema • Ophthalmology

Ocular Toxicity Study of KSI-101 Demonstrates Tolerability after Intravitreal Administration in Cynomolgus Monkeys (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Ocular Inflammation • Ophthalmology • Retinal Disorders • IL6